Genmab Stock Nasdaq Copenhagen
Stocks
DK0010272202
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 129B 20.09B 17.29B 16.27B 14.86B 27.8B 1,897B 27.88B 192B 74.6B 973B 75.45B 73.81B 3,136B | P/E 2026 * |
27.4x | P/E 2027 * | 19.3x |
|---|---|---|---|---|---|
| Enterprise Value | 148B 23.08B 19.86B 18.68B 17.07B 31.93B 2,179B 32.02B 221B 85.67B 1,118B 86.66B 84.77B 3,601B | EV / Sales 2026 * |
5.13x | EV / Sales 2027 * | 4.16x |
| Free-Float |
94.3% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Genmab
| 1 day | -0.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2010-05-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 2020-02-29 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 2024-08-15 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 2003-10-31 | |
| Director/Board Member | 58 | 2014-12-31 | |
| Director/Board Member | 75 | 2014-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.33% | +4.14% | - | - | 20.4B | |
| -1.79% | -2.27% | +50.90% | +89.03% | 69.02B | |
| -2.06% | -0.18% | +41.53% | +88.17% | 66.32B | |
| -0.31% | +6.54% | -11.39% | +457.82% | 27.66B | |
| -3.00% | -2.90% | +39.40% | +9.41% | 26.54B | |
| +0.86% | +1.65% | +0.25% | -14.78% | 25.84B | |
| -1.46% | +0.42% | +24.07% | -18.70% | 20.4B | |
| -2.96% | -15.21% | +210.71% | +370.84% | 17.63B | |
| -1.49% | -4.88% | -0.41% | +530.26% | 15.15B | |
| -0.20% | +8.37% | +57.87% | +159.50% | 14.65B | |
| Average | -1.27% | -0.35% | +45.88% | +185.73% | 31.47B | |
| Weighted average by Cap. | -1.45% | -0.34% | +42.56% | +144.95% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 28.95B 4.5B 3.87B 3.64B 3.33B 6.23B 425B 6.24B 43.05B 16.71B 218B 16.9B 16.53B 702B | 33.71B 5.24B 4.51B 4.24B 3.88B 7.25B 495B 7.27B 50.14B 19.46B 254B 19.68B 19.25B 818B |
| Net income | 4.93B 766M 659M 620M 566M 1.06B 72.31B 1.06B 7.33B 2.84B 37.1B 2.88B 2.81B 120B | 7.16B 1.11B 958M 901M 823M 1.54B 105B 1.54B 10.65B 4.13B 53.94B 4.18B 4.09B 174B |
| Net Debt | 19.19B 2.98B 2.57B 2.42B 2.21B 4.13B 282B 4.14B 28.55B 11.08B 145B 11.2B 10.96B 466B | 11.03B 1.71B 1.47B 1.39B 1.27B 2.37B 162B 2.38B 16.4B 6.36B 83.03B 6.44B 6.3B 267B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
